v3.25.3
Revenues
 9 Months Ended
Sep. 30, 2025
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
We operate our business in one operating segment, which also represents one reportable segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. A substantial portion of ROW product sales relates to products sold in Europe.
Revenues were as follows (in millions):
Three months ended September 30,
20252024
U.S.ROWTotalU.S.ROWTotal
Prolia$806 $333 $1,139 $683 $362 $1,045 
Repatha442 352 794 281 286 567 
ENBREL574 6 580 817 8 825 
Otezla473 112 585 460 104 564 
XGEVA357 182 539 373 168 541 
EVENITY417 124 541 289 110 399 
TEPEZZA518 42 560 482 6 488 
BLINCYTO236 156 392 237 90 327 
Nplate333 124 457 345 111 456 
KYPROLIS225 134 359 238 140 378 
Aranesp103 254 357 105 232 337 
TEZSPIRE(1)
377 — 377 269 — 269 
KRYSTEXXA320 — 320 310 — 310 
Vectibix162 122 284 132 150 282 
Other products(2)
1,408 445 1,853 958 405 1,363 
Total product sales(3)
$6,751 $2,386 9,137 $5,979 $2,172 8,151 
Other revenues420 352 
Total revenues$9,557 $8,503 
Nine months ended September 30,
20252024
U.S.ROWTotalU.S.ROWTotal
Prolia$2,271 $1,089 $3,360 $2,110 $1,099 $3,209 
Repatha1,1461,0002,146 8247921,616 
ENBREL1,675191,694 2,280212,301 
Otezla1,3283121,640 1,1853171,502 
XGEVA1,0645731,637 1,1385261,664 
EVENITY1,1323691,501 8063261,132 
TEPEZZA1,349971,446 1,379 12 1,391 
BLINCYTO7793671,146 555280835 
Nplate7623771,139 7493701,119 
KYPROLIS6733881,061 7124191,131 
Aranesp3017551,056 2967381,034 
TEZSPIRE(1)
1,004— 1,004 676— 676 
KRYSTEXXA905— 905 839 — 839 
Vectibix441415856 385414799 
Other products(2)
3,907 1,2835,190 2,858 1,2044,062 
Total product sales(3)
$18,737 $7,044 25,781 $16,792 $6,518 23,310 
Other revenues1,104 1,028 
Total revenues$26,885 $24,338 
_______
(1)    TEZSPIRE is marketed by our collaborator AstraZeneca outside the United States.
(2)    Consists of product sales of our non-principal products.
(3)    Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2025 and 2024.